Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase 1 trial.
Apresentado por Dr. Aditya Bardia, Massachussets General Hospital, Boston – USA, no Congresso da ESMO Breast
Dr. José Fernando
10/05/2021